<DOC>
	<DOCNO>NCT01525147</DOCNO>
	<brief_summary>A block-randomized , double-blind , placebo-controlled , single-dose escalating , phase I clinical trial evaluate safety , tolerability pharmacokinetics YHB1411-2 healthy male volunteer</brief_summary>
	<brief_title>Phase I Clinical Trial Evaluate Safety , Tolerability Pharmacokinetics YHB1411-2 Healthy Male Volunteers</brief_title>
	<detailed_description>First human Study</detailed_description>
	<mesh_term>Rheumatic Fever</mesh_term>
	<criteria>1 . Healthy male volunteer age 20 45 year old time screen 2 . Volunteers weigh 50 kg body mass index 18.0 ~ 28.0 kg/m2 3 . Volunteers sign write informed consent voluntarily , prior procedure , use form approve local Institutional Review Board detail explanation purpose , content , characteristic drug 1 . Have history presence clinically significant disease liver , kidney , gastrointestinal tract , nervous system , respiratory system , endocrine system , bloodâ€¢tumor , cardiovascular , urinary system , mental disorder 2 . Presence current tuberculosis latent tuberculosis history tuberculosis ( confirm chest Xray test tuberculin skin test ) 3 . Have active infection chronic topical infection 4 . Have history hospitalization receive antibiotic due serious infection within 1 month prior first administration 5 . Have know hypersensitivity biologicals 6 . Have AST ( SGOT ) or/and ALT ( SGPT ) &gt; 1.5 time normal upper limit time screen 7 . Shown positive result HBsAg , HCV Ab , HIV Ab test 8 . Have history drug abuse show positive reaction drug abuse urine test time screen 9 . Received biological drug include monoclonal antibody product protein drug within last 6 month prior first administration 10 . Participated clinical trial within 2 month prior first administration Investigational Product 11 . Have donate whole blood within 2 month prior first administration Investigational Product , donate blood component receive transfusion within 1 month prior first administration Investigational Product 12 . Subject drink continuously ( 21 units/week , 1 unit = 10 g pure alcohol ) quit drink hospitalize 13 . Smoker ( Subject enrol he/she quit smoking within 3 month first administration Investigational Product ( Day 1 ) ) 14 . Subject judge ineligible principal investigator subinvestigator accord various reason include abnormal test result ( clinical laboratory test , chest Xray test , 12lead ECG )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>